{"filings":[{"id":96756,"accession_number":"0001493152-26-021629","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syra Health posts first profitable quarter in Q1 2026; net income $241K, EPS $0.02, revenue up 22%","event_type":"earnings","confidence":"high","bullets":["Net income of $241,000 vs net loss of $(472,265) in Q1 2025; EPS $0.02 vs ($0.04).","Total revenue $2.3M (+22% YoY); population health solutions grew 46% to $1.8M.","Gross margin expanded to 42.7%, up 11 ppt from 31.7%.","Cash on hand $2.9M; no long-term debt as of March 31, 2026.","Adjusted EBITDA improved to $244,495 from $(462,239) in prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":2273520.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110952,"accession_number":"0001493152-26-009799","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syra Health FY2025 net loss down 76%; Population Health revenue up 157% to $5.3M","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $7.2M (-9% YoY); net loss improved 76% to ($896K) from ($3.8M).","EPS improved to ($0.08) from ($0.50) in FY2024; Q4 2025 net loss ($135K) vs ($504K) Q4 2024.","Population Health revenue grew 157% to $5.3M; gross margin expanded to 34.4% from 20.7%.","Operating expenses down 37% to $3.4M; adjusted EBITDA improved to ($863K) from ($3.7M).","Company expects profitability by year-end 2026; cash $1.6M, no long-term debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127583,"accession_number":"0001493152-25-028301","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Syra Health appoints Gregory R. Alexander as CEO effective Jan 5, 2026","event_type":"leadership","confidence":"high","bullets":["New CEO Gregory R. Alexander receives $251k base salary, 30% target bonus, and 110,537 RSUs.","Also granted 257,920 stock options (Class B) and 368,458 performance stock units.","Alexander previously served as SVP at Ellipsis Health, Chief Growth Officer at CitizensRx (tripled sales), and market leader at Lumeris (expanded from 3 to 11 markets).","He will replace interim CEO Priya Prasad; appointment follows an extensive national search.","Alexander is a former U.S. Marine Corps officer with over 20 years of P&L experience in healthcare."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127582,"accession_number":"0001493152-25-024059","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Syra Health amends charter to modify Class B conversion triggers and transfer rules","event_type":"other_material","confidence":"high","bullets":["Stockholders approved charter amendments on Nov 14, 2025; Certificate of Amendment filed and effective Nov 18, 2025.","Removed provision requiring automatic conversion of Class B common stock upon death of a Class B stockholder.","Expanded permissible transferees for Class B shares without conversion to include immediate family, heirs, successors, and assigns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127581,"accession_number":"0001493152-25-023488","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Syra Health shareholders approve Class B charter amendments and elect directors","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected; top vote-getter Priya Prasad 9,093,067 for, 4,508,108 against.","Ratified M&K CPAs as auditor: 14,955,596 for, 369,733 against, 523,081 abstain.","Approved amendment to delete automatic conversion of Class B shares on death: 8,917,010 for, 4,632,013 against.","Approved amendment allowing transfer of Class B shares to family members: 8,880,105 for, 4,631,020 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127580,"accession_number":"0001493152-25-021784","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syra Health Q3 revenue falls 26% to $1.7M; population health up 96%, net loss down 46%","event_type":"earnings","confidence":"high","bullets":["Revenue $1.7M, down from $2.3M YoY due to federal spending cuts.","Population Health segment grew 96% YoY to $1.28M.","Gross margin improved 300 bps to 33%; net loss narrowed 46% to ($225,902).","EPS improved to ($0.02) from ($0.06); adjusted EBITDA improved to ($218,601).","Cash $2.0M, no long-term debt; SyraBot live with managed care org serving 400k members."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":5491944.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144363,"accession_number":"0001641172-25-024383","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Syra Health appoints Radhika Mereddy to Board of Directors","event_type":"leadership","confidence":"high","bullets":["Radhika Mereddy appointed to Syra Health's Board on August 13, 2025.","Compensation consistent with other non-employee directors.","No arrangement or understanding with any person regarding her selection.","Mereddy is a principal stockholder in RAD CUBE LLC, STVentures, NLogix IT, and SKL Demand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144362,"accession_number":"0001641172-25-023118","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syra Health Q2 net loss narrows 95% to $64K; gross margin surges to 38.7%","event_type":"earnings","confidence":"high","bullets":["Net loss of $64K ($0.01 EPS) vs $1.4M loss ($0.21 EPS) in Q2 2024; adjusted EBITDA improved to ($54K) from ($1.4M).","Gross margin rose 2,090 bps to 38.7%; operating expenses declined 53% YoY to $816K.","Population Health revenue up 197% to $1.6M, driven by $5.8M FSSA contract for HCBS training.","Cash $2.3M, no long-term debt; negotiating $5.8M CMHW mental health contract with Indiana FSSA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":3803973.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144361,"accession_number":"0001641172-25-021576","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Deepika Vuppalanchi resigns from Syra Health board for personal reasons","event_type":"leadership","confidence":"high","bullets":["Deepika Vuppalanchi resigned from the Board of Directors on July 28, 2025, for personal reasons.","Vuppalanchi continues as Chief Executive Officer; her board resignation does not affect her executive role.","The company did not announce any replacement director or board committee changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162718,"accession_number":"0001641172-25-015349","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Syra Health terminates CEO Deepika Vuppalanchi for cause; CFO appointed interim CEO","event_type":"leadership","confidence":"high","bullets":["Board terminated CEO Deepika Vuppalanchi for cause on June 13, 2025.","Priya Prasad, previously CFO and COO, appointed interim CEO effective June 16, 2025.","Termination of employment agreement dated April 5, 2021 for cause."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162717,"accession_number":"0001641172-25-011732","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Syra Health board launches national CEO search; Vuppalanchi interim","event_type":"leadership","confidence":"high","bullets":["Board initiates a national search for a new CEO to succeed current CEO Dr. Deepika Vuppalanchi.","Dr. Vuppalanchi will serve as interim CEO until a successor is appointed.","Co-founder Vuppalanchi is expected to remain on the leadership team post-transition.","Transition is described as a strategic succession plan for next growth phase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}